-
Clinical Trials & Development2 months agoAbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
AbbVie’s etentamig has a relatively cleaner safety profile and an administration schedule that could give it an edge over other BCMA-targeting multiple myeloma therapies on the...
-
Clinical Trials & Development2 months agoAbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 CERVINO study1 evaluating etentamig, an investigational BCMA...
-
Clinical Trials & Development2 months agoPsilocybin Prevents Chemotherapy-Related Peripheral Neuropathy in Mice
A study found that psilocybin given before chemotherapy prevented the onset of nerve injury in mouse models, even after repeated treatment cycles, and also protected tumor-bearing...
-
Clinical Trials & Development2 months agoSTAT+: Seattle scientists launch $95 million AI biology effort
Ultragenyx drug fails pivotal Phase 3, FDA's success at regulating unproven stem cells, and other biotech news
-
Clinical Trials & Development2 months agoRevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer
The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in...
-
Clinical Trials & Development2 months agoSummit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to...
-
Clinical Trials & Development2 months agoSTAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more
The latest pharma news from the Pharmalot campus via the Pharmalittle newsletter
-
Clinical Trials & Development2 months agoAutoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
-
Clinical Trials & Development2 months agoUltragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing strategic review
The success of apazunersen in a Phase 3 trial for Angelman syndrome was a key driver of Ultragenyx’s value, according to William Blair, and the asset’s...
-
Clinical Trials & Development2 months agoSTAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial
Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
